{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:16:02Z","timestamp":1793711762511,"version":"4.6.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Abiraterone, an androgen deprivation therapy, has been used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). It has been associated with increased risks of hypokalaemia and cardiac disorders. We report a case of torsades de pointes (TdP) associated with abiraterone use and refractory hypokalaemia in a man with mCRPC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 78-year-old man with mCRPC presented to the emergency room for generalized weakness. Laboratory results revealed a potassium level of 2.2 mmol\/L (3.5\u20135.0), magnesium level of 2.4 mg\/dL (1.6\u20132.5), and normal kidney and hepatic functions. Initial electrocardiogram showed atrial fibrillation with rapid ventricular rate of 106 b.p.m., frequent premature ventricular contractions, and a QTc of 634 ms. The patient had multiple episodes of TdP, became pulseless and underwent advanced cardiac life support, including defibrillation. Despite a total of 220 mEq of intravenous potassium chloride, his potassium level only improved to 2.8 mmol\/L. He received spironolactone and amiloride to promote urinary potassium reabsorption in addition to hydrocortisone, in an effort to reduce abiraterone\u2019s effect on increasing mineralocorticoid synthesis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Abiraterone has been widely used in mCRPC since its approval by the Food and Drug Adminstration in 2011. Regulatory guidelines and standardized close QTc and electrolyte monitoring in patients may help prevent fatal arrhythmias associated with abiraterone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab462","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:39:35Z","timestamp":1637213975000},"source":"Crossref","is-referenced-by-count":6,"title":["Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-8724","authenticated-orcid":false,"given":"Mariam","family":"Riad","sequence":"first","affiliation":[{"name":"Internal Medicine Department, University of Alabama, Huntsville Regional Campus, Huntsville, AL 35801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2318-5426","authenticated-orcid":false,"given":"Jeffery Scott","family":"Allison","sequence":"additional","affiliation":[{"name":"CardiologyDepartment, TheHeart Center, Huntsville Hospital, Huntsville, AL 35801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-3302","authenticated-orcid":false,"given":"Shahla","family":"Nayyal","sequence":"additional","affiliation":[{"name":"PharmacyDepartment, University of Colorado, Denver, Skaggs School of Pharmacy, Denver, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-6988","authenticated-orcid":false,"given":"AbdulWahab","family":"Hritani","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University of Alabama, Huntsville Regional Campus, Huntsville, AL 35801, USA"},{"name":"CardiologyDepartment, TheHeart Center, Huntsville Hospital, Huntsville, AL 35801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2022032914031834100_ytab462-B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2022032914031834100_ytab462-B2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"key":"2022032914031834100_ytab462-B3","author":"CredibleMeds::Login [Internet]","year":"2021"},{"key":"2022032914031834100_ytab462-B4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"2022032914031834100_ytab462-B5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2022032914031834100_ytab462-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2022032914031834100_ytab462-B7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022032914031834100_ytab462-B8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2006.08.057","article-title":"Long QT syndrome in adults","volume":"49","author":"Sauer","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022032914031834100_ytab462-B9","first-page":"124","article-title":"Life threatening torsades de pointes due to abiraterone-induced hypokaelemia in a patient with metastatic prostate cancer","volume":"129","author":"Khan","year":"2016","journal-title":"N Z Med J"},{"key":"2022032914031834100_ytab462-B10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1060028014555362","article-title":"Abiraterone acetate-induced life-threatening torsade de pointes","volume":"49","author":"Rodieux","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2022032914031834100_ytab462-B11","author":"Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer\u2014PubMed","year":"2021"},{"key":"2022032914031834100_ytab462-B12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022032914031834100_ytab462-B13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"key":"2022032914031834100_ytab462-B14","first-page":"753","article-title":"Torsade de pointes with sotalol overdose treated successfully with lidocaine","volume":"14","author":"Assimes","year":"1998","journal-title":"Can J Cardiol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytab462\/41158350\/ytab462.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/12\/ytab462\/43060813\/ytab462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/12\/ytab462\/43060813\/ytab462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T14:03:39Z","timestamp":1648562619000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab462\/6429278"}},"subtitle":[],"editor":[{"given":"Patrick","family":"Badertscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Richard","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Stefano","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Matteo","family":"Parollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Anthony Paulo","family":"Sunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab462","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,11,16]]},"article-number":"ytab462"}}